Clinical Trial

A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia

Study acronym: ASCEND-QW
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is researching an experimental drug called alirocumab, referred to as "study drug". In the United States, alirocumab is approved for the treatment of hypercholesterolemia (high blood cholesterol levels). The aim of the study is to see how safe and effective alirocumab is when given weekly to adult participants who have hypercholesterolemia. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug once a week * How much study drug is in the blood at different times
Protocol Amendment History 5 changes
notable Trial sites expanded: 30 -> 34 locations 2026-07-23
notable Trial sites expanded: 6 -> 30 locations 2026-07-09
critical Recruitment opened 2026-06-11
notable Trial sites expanded: 0 -> 6 locations 2026-06-11
notable Primary completion pushed: 2026-10-20 -> 2026-12-29 2026-06-11
Trial Details
NCT Number NCT07477704
Lead Sponsor Regeneron Pharmaceuticals
Conditions Hypercholesterolemia
Enrollment 420 participants
Start Date 2026-06-17
Primary Completion 2026-12-29 (estimated)
Study Completion 2027-02-23 (estimated)
Updated on ClinicalTrials.gov 2026-07-22